欧林生物(688319) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥119,099,915.08, a decrease of 13.74% year-on-year[5] - The net profit attributable to shareholders was ¥1,737,688.79, down 80.98% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,168,246.26, a decline of 113.03% year-on-year[5] - Basic earnings per share for Q3 2023 were ¥0.0043, reflecting an 80.89% decrease from the previous year[6] - Total operating revenue for the first three quarters of 2023 was CNY 352,299,329.93, a decrease of 4.3% compared to CNY 370,775,967.99 in the same period of 2022[19] - Net profit for the third quarter of 2023 was CNY 26,052,088.24, down 35.2% from CNY 40,176,540.76 in the same quarter of 2022[20] - The basic earnings per share for the third quarter of 2023 was CNY 0.0747, compared to CNY 0.0991 in the same quarter of 2022, a decrease of 24.4%[21] Research and Development - Total R&D investment for the quarter was ¥42,926,295.77, a reduction of 65.34% compared to the same period last year[6] - R&D investment accounted for 36.04% of operating revenue, a decrease of 53.67 percentage points year-on-year[6] - Research and development expenses increased to CNY 80,280,605.06 in the first three quarters of 2023, compared to CNY 70,163,513.83 in 2022, reflecting a growth of 14.5%[19] - The company plans to continue focusing on R&D and market expansion despite the current financial challenges[9] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,506,575,846.57, an increase of 1.87% from the end of the previous year[6] - The company's total assets reached ¥1,506,575,846.57, compared to ¥1,478,871,193.65 at the end of 2022, reflecting a growth of about 1.9%[16] - Total liabilities decreased to ¥565,885,370.71 from ¥587,022,458.86, showing a reduction of approximately 3.4%[17] - The company's non-current assets increased to ¥580,820,672.45 from ¥542,976,667.88, marking an increase of around 6.9%[16] - The total equity of the company was reported at ¥940,690,475.86, up from ¥891,848,734.79, indicating an increase of approximately 5.5%[17] - The total equity attributable to shareholders of the parent company increased to CNY 924,619,836.26 from CNY 881,625,176.44, marking a growth of 4.9%[18] Cash Flow - As of September 30, 2023, the company's cash and cash equivalents amounted to ¥350,266,768.31, an increase from ¥269,231,404.17 at the end of 2022, representing a growth of approximately 30.1%[15] - Cash flow from operating activities for the first three quarters of 2023 was negative at CNY -10,436,085.88, an improvement from CNY -127,732,041.22 in the same period of 2022[24] - Cash inflow from investment activities was CNY 146,017,632.88 in the first three quarters of 2023, down from CNY 348,355,065.54 in 2022, representing a decline of 58.1%[24] - Total cash flow from investing activities decreased to $122,620,764.78 from $225,520,562.84 year-over-year, a decline of approximately 45.6%[25] - The net cash flow from financing activities was $69,662,910.27, a decrease from $101,802,218.03, reflecting a decline of about 31.5%[25] Expenses - The company experienced an increase in management expenses, particularly in share-based payment expenses, contributing to the decline in net profit[9] - Operating costs for the first three quarters of 2023 were CNY 328,847,307.58, up from CNY 315,703,844.87 in 2022, indicating an increase of 4.1%[19] - The company reported a decrease in sales expenses to CNY 160,313,438.20 in the first three quarters of 2023, down from CNY 168,868,360.98 in 2022, a reduction of 5.1%[19] Inventory and Receivables - Accounts receivable stood at ¥492,144,166.50, slightly up from ¥491,171,654.30, indicating a marginal increase of 0.2%[15] - The inventory level was reported at ¥76,776,556.91, down from ¥78,521,680.38, reflecting a decrease of approximately 2.2%[16] - The company’s prepayments increased significantly to ¥4,810,314.56 from ¥2,345,256.61, representing a growth of about 104.5%[16] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - The company has not adopted new accounting standards or interpretations for the current year[25]